Mor­phoSys taps Baven­cio lead for US op­er­a­tions; Two top FDA of­fi­cials move to in­dus­try

→ Hav­ing built out a com­mer­cial foot­print in the US and led the launch of Baven­cio for Mer­ck KGaA, David Trexler is tak­ing up a new role as pres­i­dent of Ger­man biotech Mor­phosys’ US sub­sidiary. Fol­low­ing a dual list­ing on the Nas­daq $MOR last year, Mor­phoSys is plot­ting a swift roll­out for MOR208 once the FDA ap­proves its use in dif­fuse large B cell lym­phoma — now with a guid­ing hand from Trexler, who’s al­so worked sales and mar­ket­ing for Ei­sai’s US on­col­o­gy unit.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.